

To view this email as a web page, go [here](#).

[View in your browser](#)



INNOVATION AND COMMERCIALIZATION

Mar. 5, 2025

OHSU Innovates



LEADERSHIP MESSAGE

Academic research centers are society's greatest conduit to advancing medicine, technology, agriculture and public health. Discoveries born from

university research leads to discoveries that translate into products and services such as insulin, penicillin, ultrasound and PET/CT imaging, pacemaker, seatbelt, HIV antiviral therapies, the barcode, Honeycrisp™ apples, and the polio vaccine. We create and fuel existing industry sectors driving economic development in rural and urban regions. University research has supported greater than 200 drugs and vaccines through public-private partnerships since the Bayh-Dole Act was enacted in 1980, which fueled thousands of start-up companies, and contributed \$865 billion to U.S. gross domestic product from 1996 to 2017. We're pretty certain you've heard of Google! OHSU Innovates strives to be an economic development resource for the community we serve, and we must also recognize OHSU's multi-pronged role in education, public service, healthcare, and dissemination of knowledge learned from research and clinical care.

Travis Cook, M.S., M.B.A, CLP

Senior Director, Technology Transfer

Aditi Martin, Ph.D.

Senior Director, Collaborations and Entrepreneurship

FEATURED STORY

OHSU Innovation Awardees



Katie Blise, Ph.D., David Lewinson, M.D., Ph.D., Deborah Lewinsohn, M.D., Joanna Pucilowska, M.S., Ph.D., Kenneth Riley, and Sam Sivagnanam, M.S. have been named the 2025 OHSU Innovation Awardees by the OHSU Innovates community. In addition, Klaus Früh, Ph.D., has been elected as a Fellow of the National Academy of Inventors. This group has demonstrated an outstanding passion for innovation and collaboration and each works closely with the OHSU Innovates network. More details about the awardees and their innovative research can be found in the 2025 OHSU Innovation Awards announcement. Come celebrate these awardees and enjoy a networking happy hour with complimentary drinks and hors d'oeuvres at the in-person 2025 Innovation Awards event. [Read more about the awardees and their innovative science in the 2025 OHSU Innovation Awards announcement.](#)

Register now to attend the in-person awards celebration, which includes a networking happy hour, to be held March 12, 4-7 p.m. [Register for the event through Eventbrite.](#)

RyboDyn, Inc. Closes a \$4M pre-seed financing round

Congratulations to OHSU startup company [RyboDyn](#) on the successful closing of a \$4 million pre-seed financing round to advance its mission of targeting the dark proteome for the development of novel immunotherapies. RyboDyn's proprietary RNA sequencing technology was originally developed at the Knight Cancer Institute Cancer Early Detection Advanced Research center by former OHSU researchers Corey Dambacher, Ph.D., Ashley Woodfin, M.S., and colleagues. The first datasets generated using this RNA sequencing method revealed a hidden or "cryptic" human proteome consisting of thousands of previously undiscovered proteins. Read more about the recent announcement in the [press release](#).

David Huang inducted to the National Inventors Hall of Fame

Congratulations to [David Huang, M.D., Ph.D.](#), one of seventeen inventors in the 2025 class of inductees for the National Inventors Hall of Fame. Huang is recognized for his contributions as a coinventor of optical coherence tomography, a method for imaging subsurface structure of biological tissue in unprecedented detail. In partnership with the United States Patent and Trademark Office (USPTO), the Hall of Fame will honor these Inductees on May 8 in Washington DC. Read more about the 2025 class of inductees in the [press release](#).

Congratulations to the recipients of the Biomedical Innovation Program Grants

The Oregon Clinical and Translational Research Institute's Biomedical Innovation Program, or BIP, has named five projects as recipients in the program's device, diagnostic and software track. This BIP track supports medical device and diagnostic technologies that address a significant

clinical problem, achieve cost savings, improve research efficiency or improve quality of patient care. Congratulations to the OHSU awardees [Peter Jacobs, Ph.D.](#), Evan Fontaine, M.B.M.E., Yasmeen Elsayaf, M.D., [Alireza Karimi, Ph.D.](#), [Katie Blise, Ph.D.](#), and [Sam Sivagnanam, M.S.](#) Read more about the grants and projects in the [OHSU Now post](#).

Autobahn Therapeutics Announces Initiation of a new Phase 2 Trial

OHSU startup company [Autobahn Therapeutics](#) announced in January the initiation of a Phase 2 clinical trial evaluating ABX-002, a highly potent, oral, thyroid hormone beta receptor selective agonist, as an adjunctive treatment in adults with bipolar depression. The original work developing these therapeutic compounds began in the lab of [Thomas Scanlan, Ph.D.](#) ABX-002 is also in Phase 2 development for the adjunctive treatment of major depressive disorder. Read more about the news in the [Autobahn announcement](#).

FEATURED EVENT

Oregon Innovation Showcase



The Oregon Innovation Showcase will develop and strengthen relationships with deep tech investors, including those from out of state, by highlighting Oregon as a premier hub for innovation and startups. The event will feature successful Oregon-grown companies, emerging startups seeking funding, and the supportive state ecosystem that de-risks investments. Find more details on the [Oregon Innovation Showcase website](https://oregoninnovationshowcase.com).

WHEN**May 19-20**

WHERE**The Sentinel Hotel, 614 SW 11th Ave,
Portland, Oregon**

WHOResearchers, students, post-docs, entrepreneurs,
and investors

COST\$49.00 - \$299.00

UPCOMING EVENTS

MAR. 6 [Oregon Bio Women: The Leadership Forge](#)

MAR. 6 [Accelerate Happy Hour](#)

MAR. 12 [OBI Virtual Lunch & Learn: Introduction to Drug Regulation and the IND Process Part 1](#)

MAR. 13 [ITHS Biomedical Innovation Fireside Chat Series 2025: Strategies for Increasing Diversity in Clinical Trials](#)

MAR. 19 [AI and Data Community Event- TAO & Women in Big Data](#)

APR. 10 [BIPOC in Bioscience](#)

APR. 23 - 24 [Life Science Innovation Northwest 2025](#)

APR. 29 [Bio on the Rocks 2025](#)

TECHNOLOGIES

Featured technologies available for licensing

A selection of OHSU-developed technologies available for licensing to industry partners. For more technologies visit the [OHSU Technology Portal](#).

[OHSU 2939](#) - Photoactivatable modulation of antibody binding

[OHSU 3321](#) - Machine-learning based forecasting of visual field deficits for glaucoma management

Newly Licensed or Optioned OHSU Technologies

Congratulations to the inventors of these technologies, which were recently licensed or optioned to outside partners.

[OHSU 1771](#) - Materials from the BioLibrary

[OHSU 3191](#) - Workplace Mental Health Support Training for Leaders ([Leslie Hammer, Ph.D.](#))

U.S. Patents Issued

Congratulations to the OHSU inventors of this recently issued U.S. patent.

[Patent 12,193,815](#) - Systems and methods for capillary oximetry using optical coherence tomography

SPONSORS

Thank you to our current sponsors for their support of OHSU Innovates



Questions? Contact us at innovates@ohsu.edu

This bi-monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, Oregon Clinical and Translational Research Institute and the Knight Cancer Institute.

©2025 OHSU

This email was sent by OHSU

3181 S.W. Sam Jackson Park Rd.
Portland, OR, 97239, US

This email was sent to: garrisni@ohsu.edu

[Unsubscribe](#) | [Manage subscriptions](#) | [Update profile](#)

[OHSU email terms of service](#) | [OHSU privacy policy](#)